Johnson & Johnson $JNJ Shares Sold by OLD Second National Bank of Aurora

OLD Second National Bank of Aurora decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 29,245 shares of the company’s stock after selling 663 shares during the period. Johnson & Johnson makes up approximately 1.0% of OLD Second National Bank of Aurora’s portfolio, making the stock its 26th biggest position. OLD Second National Bank of Aurora’s holdings in Johnson & Johnson were worth $4,467,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Elios Financial Group Inc. grew its position in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after purchasing an additional 66 shares during the last quarter. Atlantic Family Wealth LLC grew its position in Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after purchasing an additional 67 shares during the last quarter. MBA Advisors LLC grew its position in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after purchasing an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its position in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after purchasing an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc grew its position in Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after purchasing an additional 69 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.4%

JNJ stock opened at $188.51 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.78. The firm has a market cap of $453.98 billion, a PE ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. The firm has a 50 day simple moving average of $176.18 and a 200 day simple moving average of $162.83. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the business earned $2.82 earnings per share. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on JNJ shares. Bank of America upped their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Johnson & Johnson in a report on Saturday, September 27th. Royal Bank Of Canada increased their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $188.88.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.